Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

13 July 2022 : Clinical Research

Iwona Homa-Mlak^1ACDEF*, Marcin Mazurek^1BCEF, Aleksandra Majdan

^1DEF, Radosław Mlak^1ACDE, Maria Majdan

^2ADEF, Teresa Mełecka-Massalska^1ADEF

DOI: 10.12659/MSM.936534

Med Sci Monit 2022; 28:e936534

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 5 Differences in calprotectin value depending on clinical manifestation of SLE in the study group.

Variable	Median	p
Form of disease		0.3768
Kidney	3.05
Articular	3.18
Dermal	3.08
Neuropsychiatric	3.82
Haematological	3.16

Photosensitivity		0.7673
Yes	3.10
No	3.10

Skin changes		0.7673
Yes	3.10
No	3.11

Erosions of the mucous membranes		0.3572
Yes	3.17
No	3.10

Tiredness		0.3173
Yes	3.11
No	3.02

Fever		0.1618
Yes	3.16
No	3.06

Raynaud’s syndrome		0.4392
Yes	3.25
No	3.09

Chair loss		0.4097
Yes	3.22
No	3.06

Myopathy		0.0277^*
Yes	3.94
No	3.09

Vasculitis		0.1049
Yes	3.25
No	3.06

Arthritis		0.9454
Yes	3.10
No	3.10

Arthralgia		0.0942
Yes	3.12
No	3.01

Pleurisy		0.1416
Yes	3.92
No	3.09

Pericarditis		0.8921
Yes	3.06
No	3.11

Epilepsy		0.4510
Yes	3.47
No	3.10

Seizures		0.0938
Yes	3.94
No	3.10

Psychosis		–
Yes	3.83
No	3.10

Proteinuria		0.0711
Yes	3.06
No	3.21

Hematuria		0.4687
Yes	3.05
No	3.11

Chronic kidney disease		0.3191
Yes	3.04
No	3.11

Hepatomegaly		0.3272
Yes	3.76
No	3.10

Splenomegaly		0.2922
Yes	3.43
No	3.11

Lymphadenopathy		0.4022
Yes	3.45
No	3.10
^* Statistically significant results.

Back to the Article